Keros Therapeutics (KROS) EBIAT: 2019-2025
Historic EBIAT for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to -$7.3 million.
- Keros Therapeutics' EBIAT rose 86.25% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 135.50%. This contributed to the annual value of -$187.4 million for FY2024, which is 22.46% down from last year.
- According to the latest figures from Q3 2025, Keros Therapeutics' EBIAT is -$7.3 million, which was up 76.28% from -$30.7 million recorded in Q2 2025.
- Keros Therapeutics' 5-year EBIAT high stood at $148.5 million for Q1 2025, and its period low was -$53.0 million during Q3 2024.
- Its 3-year average for EBIAT is -$20.9 million, with a median of -$39.4 million in 2023.
- As far as peak fluctuations go, Keros Therapeutics' EBIAT crashed by 328.21% in 2022, and later surged by 444.32% in 2025.
- Keros Therapeutics' EBIAT (Quarterly) stood at -$6.9 million in 2021, then crashed by 328.21% to -$29.7 million in 2022, then tumbled by 35.42% to -$40.2 million in 2023, then declined by 14.37% to -$46.0 million in 2024, then soared by 86.25% to -$7.3 million in 2025.
- Its last three reported values are -$7.3 million in Q3 2025, -$30.7 million for Q2 2025, and $148.5 million during Q1 2025.